Skip to main content

Table 2 BCVA, CRT, CNV blood flow area, and IOP before and after treatment (N = 40)

From: Efficacy and safety of intravitreal injections of conbercept for the treatment of idiopathic choroidal neovascularization

Indices (mean ± SD)

Preoperative

1 month

3 months

6 months

12 months

BCVA (LogMAR)

0.45 ± 0.15

0.28 ± 0.11* ^

0.24 ± 0.13* ^

0.24 ± 0.12* ^

0.21 ± 0.10*

*p value

< 0.0001

< 0.0001

< 0.0001

< 0.0001

^p value

0.0033

0.2683

0.4451

CRT (μm)

314.2 ± 35.36

257.0 ± 30.35* ^

254.1 ± 31.28* ^

247.7 ± 29.24* ^

251.1 ± 29.31*

*p value

< 0.0001

< 0.0001

< 0.0001

< 0.0001

^p value

 

< 0.0001

0.6566

0.6103

CNV area (mm2)

0.20 ± 0.05

0.13 ± 0.04* ^

0.12 ± 0.04* ^

0.13 ± 0.05* ^

0.11 ± 0.03*

*p value

< 0.0001

< 0.0001

< 0.0001

< 0.0001

^p value

 

0.0361

0.7281

0.1057

IOP (mmHg)

15.45 ± 2.71

15.48 ± 2.25# ^

14.60 ± 2.48# ^

15.75 ± 2.24# ^

14.88 ± 2.55#

#p value

0.9632

0.1899

0.5911

0.2778

^p value

 

0.2686

0.6264

0.1073

  1. BCVA best-corrected visual acuity, logMAR logarithm of minimal angle of resolution, CRT central retinal thickness, CNV choroidal neovascularization, IOP intraocular pressure. *P < 0.05, #P > 0.05 compared with the data before treatment. ^vs data at 12 months. The independent sample t-test or Mann-Whitney test was used to compare the values at 1, 3, and 6 months after treatment with the last follow-up. The paired t-test or Wilcoxon signed-rank test was used to compare the values after treatment with those before treatment